ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
-0,80%
Bitcoin
67 250,00
-1,63%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Travere Therapeutics Inc (TVTX)

  7. Travere Therapeutics Inc (TVTX) Actualités

TVTX

Travere Therapeutics (TVTX)

Travere Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TVTX
DateHeureSourceTitreSymboleSociété
15/05/202423h00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
13/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
10/05/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
09/05/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressNASDAQ:TVTXTravere Therapeutics Inc
08/05/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TVTXTravere Therapeutics Inc
06/05/202422h46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TVTXTravere Therapeutics Inc
06/05/202422h01GlobeNewswire Inc.Travere Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
29/04/202422h30GlobeNewswire Inc.Travere Therapeutics to Report First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
24/04/202413h05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
24/04/202409h00PR Newswire (Canada)CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
04/04/202422h30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalNASDAQ:TVTXTravere Therapeutics Inc
03/04/202422h30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses AssociationNASDAQ:TVTXTravere Therapeutics Inc
11/03/202412h05GlobeNewswire Inc.Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)NASDAQ:TVTXTravere Therapeutics Inc
23/02/202413h05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
23/02/202408h00PR Newswire (US)CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathyNASDAQ:TVTXTravere Therapeutics Inc
20/02/202414h10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TVTXTravere Therapeutics Inc
15/02/202422h01GlobeNewswire Inc.Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
14/02/202420h35Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TVTXTravere Therapeutics Inc
08/02/202422h30GlobeNewswire Inc.Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
02/02/202403h58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TVTXTravere Therapeutics Inc
01/02/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:TVTXTravere Therapeutics Inc
25/01/202422h05GlobeNewswire Inc.Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian NationsNASDAQ:TVTXTravere Therapeutics Inc
08/01/202413h00GlobeNewswire Inc.Travere Therapeutics Provides Corporate Update and 2024 OutlookNASDAQ:TVTXTravere Therapeutics Inc
02/01/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TVTXTravere Therapeutics Inc
14/12/202313h30GlobeNewswire Inc.Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)NASDAQ:TVTXTravere Therapeutics Inc
04/12/202323h14Dow Jones NewsTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU TreatmentsNASDAQ:TVTXTravere Therapeutics Inc
04/12/202322h05GlobeNewswire Inc.Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGSNASDAQ:TVTXTravere Therapeutics Inc
21/11/202322h30GlobeNewswire Inc.Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:TVTXTravere Therapeutics Inc
07/11/202322h01GlobeNewswire Inc.Travere Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
03/11/202315h46GlobeNewswire Inc.Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023NASDAQ:TVTXTravere Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TVTX

Dernières Valeurs Consultées

COIN
XIDUSD
NASDAQ
PLC
Principal ETFs Principal...
AMEX
BUFR
FT Vest Laddered Buffer ...
COIN
BLKCBTC
LSE
PHSB
BIT
CB5
Exchange Traded
BIT
P1BAZ6
BNP Paribas Issuance
BIT
P211Y8
NLBNPIT211Y8 20241220 14
BIT
P1WTD9
NLBNPIT1WTD9 20251219 25...
BIT
P17RS3
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés